Park National Corp OH increased its stake in shares of Abbott Laboratories (NYSE:ABT) by 0.4% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 602,236 shares of the healthcare product maker’s stock after buying an additional 2,236 shares during the quarter. Abbott Laboratories accounts for about 1.8% of Park National Corp OH’s investment portfolio, making the stock its 15th largest position. Park National Corp OH’s holdings in Abbott Laboratories were worth $32,135,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also added to or reduced their stakes in the company. Heritage Trust Co increased its holdings in Abbott Laboratories by 10.1% during the 2nd quarter. Heritage Trust Co now owns 2,175 shares of the healthcare product maker’s stock valued at $106,000 after purchasing an additional 200 shares in the last quarter. Winfield Associates Inc. increased its holdings in Abbott Laboratories by 3.9% during the 2nd quarter. Winfield Associates Inc. now owns 2,382 shares of the healthcare product maker’s stock valued at $116,000 after purchasing an additional 89 shares in the last quarter. Thompson Davis & CO. Inc. increased its holdings in Abbott Laboratories by 17.7% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 2,463 shares of the healthcare product maker’s stock valued at $120,000 after purchasing an additional 370 shares in the last quarter. JFS Wealth Advisors LLC increased its holdings in Abbott Laboratories by 349.0% during the 2nd quarter. JFS Wealth Advisors LLC now owns 2,694 shares of the healthcare product maker’s stock valued at $131,000 after purchasing an additional 2,094 shares in the last quarter. Finally, Motco increased its holdings in Abbott Laboratories by 213.7% during the 2nd quarter. Motco now owns 2,880 shares of the healthcare product maker’s stock valued at $140,000 after purchasing an additional 1,962 shares in the last quarter. 71.32% of the stock is owned by hedge funds and other institutional investors.

Shares of Abbott Laboratories (NYSE:ABT) opened at $55.50 on Friday. The company has a debt-to-equity ratio of 0.72, a quick ratio of 2.26 and a current ratio of 2.69. Abbott Laboratories has a 52 week low of $37.90 and a 52 week high of $56.69. The company has a market capitalization of $95,254.38, a price-to-earnings ratio of 22.71, a P/E/G ratio of 2.05 and a beta of 1.06.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Wednesday, October 18th. The healthcare product maker reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.01. Abbott Laboratories had a return on equity of 13.98% and a net margin of 8.37%. The business had revenue of $6.83 billion during the quarter, compared to analysts’ expectations of $6.72 billion. During the same period in the previous year, the firm earned $0.59 earnings per share. The firm’s quarterly revenue was up 28.8% compared to the same quarter last year. analysts anticipate that Abbott Laboratories will post 2.49 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, February 15th. Investors of record on Friday, January 12th will be paid a dividend of $0.28 per share. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.27. This represents a $1.12 dividend on an annualized basis and a dividend yield of 2.02%. Abbott Laboratories’s payout ratio is 83.47%.

Several equities research analysts have recently commented on ABT shares. Zacks Investment Research raised Abbott Laboratories from a “hold” rating to a “buy” rating and set a $61.00 target price for the company in a research note on Tuesday, October 31st. Royal Bank of Canada reissued a “buy” rating and issued a $55.00 target price on shares of Abbott Laboratories in a research note on Tuesday, October 3rd. Jefferies Group reissued a “buy” rating and issued a $65.00 target price on shares of Abbott Laboratories in a research note on Thursday, October 19th. Bank of America reissued a “buy” rating and issued a $60.00 target price (up from $56.00) on shares of Abbott Laboratories in a research note on Wednesday, October 4th. Finally, Citigroup reissued a “neutral” rating on shares of Abbott Laboratories in a research note on Thursday, October 19th. Seven equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $57.56.

In other Abbott Laboratories news, insider Alejandro D. Wellisch sold 2,153 shares of Abbott Laboratories stock in a transaction dated Wednesday, November 22nd. The stock was sold at an average price of $55.86, for a total transaction of $120,266.58. Following the transaction, the insider now directly owns 10,256 shares in the company, valued at $572,900.16. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Daniel Gesua Sive Salvadori sold 28,319 shares of Abbott Laboratories stock in a transaction dated Thursday, December 14th. The stock was sold at an average price of $54.92, for a total value of $1,555,279.48. Following the transaction, the insider now owns 102,117 shares in the company, valued at $5,608,265.64. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 616,332 shares of company stock valued at $33,579,226. 0.76% of the stock is owned by insiders.

ILLEGAL ACTIVITY NOTICE: This report was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://www.thecerbatgem.com/2017/12/16/park-national-corp-oh-has-32-14-million-position-in-abbott-laboratories-abt.html.

About Abbott Laboratories

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.